Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy.

Related Articles Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy. J Crohns Colitis. 2019 Feb 27;: Authors: Panés J, Lindsay JO, Teich N, Lindgren S, Colombel JF, Cornillie F, Flynn HA, Huyck S, Stryszak P, Yao R, Philip G, Reinisch W Abstract BACKGROUND AND AIMS: The Observational Postmarketing Ulcerative colitis Study (OPUS) was conducted to obtain the first long-term (5 years) safety data assessing treatment with originator infliximab versus conventional therapies in patients with ulcerative…

Read More

Low-dose metronidazole is associated with a decreased rate of endoscopic recurrence of Crohn’s disease after ileal resection: a retrospective cohort study.

Related Articles Low-dose metronidazole is associated with a decreased rate of endoscopic recurrence of Crohn’s disease after ileal resection: a retrospective cohort study. J Crohns Colitis. 2019 Feb 27;: Authors: Glick LR, Sossenheimer PH, Ollech JE, Cohen RD, Hyman NH, Hurst RD, Rubin DT Abstract BACKGROUND & AIMS: Recurrence of Crohn’s disease after surgical resection and primary anastomosis is an important clinical challenge. Previous studies have demonstrated the benefit of imidazole antibiotics, but have been limited by adverse events and medication intolerance. We evaluated whether administration of low-dose metronidazole (250mg…

Read More

Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort.

Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. Inflamm Bowel Dis. 2019 Feb 27;: Authors: Gregory M, Weaver KN, Hoversten P, Hicks SB, Patel D, Ciorba MA, Gutierrez AM, Beniwal-Patel P, Palam S, Syal G, Herfarth HH, Christophi G, Raffals L, Barnes EL, Deepak P Abstract BACKGROUND AND AIMS: Inflammation of the pouch after ileal pouch-anal anastomosis (IPAA) can significantly impact quality of life and be difficult to treat. We assessed the effectiveness and safety of vedolizumab in Crohn’s disease (CD) of…

Read More

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed. Aliment Pharmacol Ther. 2019 Mar;49(6):816-817 Authors: Gibson DJ, Ward MG PMID: 30811645 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30811645?dopt=Abstract

Read More

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy – early promise but more data needed. Authors’ reply.

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy – early promise but more data needed. Authors’ reply. Aliment Pharmacol Ther. 2019 Mar;49(6):817-818 Authors: Bouguen G, Siproudhis L PMID: 30811643 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30811643?dopt=Abstract

Read More

Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.

Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA. 2019 Feb 26;321(8):773-785 Authors: Walker GJ, Harrison JW, Heap GA, Voskuil MD, Andersen V, Anderson CA, Ananthakrishnan AN, Barrett JC, Beaugerie L, Bewshea CM, Cole AT, Cummings FR, Daly MJ, Ellul P, Fedorak RN, Festen EAM, Florin TH, Gaya DR, Halfvarson J, Hart AL, Heerasing NM, Hendy P, Irving PM, Jones SE, Koskela J, Lindsay JO, Mansfield JC, McGovern D, Parkes M, Pollok RCG, Ramakrishnan S, Rampton DS, Rivas MA, Russell RK, Schultz M,…

Read More

Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study.

Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study. J Crohns Colitis. 2019 Jan 25;13(Supplement_1):S616 Authors: Pineton de Chambrun G, Pariente B, Seksik P, Altwegg R, Vuitton L, Stefasnescu C, Nancey S, Aubourg A, Serrero M, Peyrin-Biroulet L, Filippi J, Viennot S, Abitbol V, Boualit M, Boureille A, Moreau J, Buisson A, Roblin X, Nachury M, Zappa M, Lambert J, Bouhnik Y, GETAID-MICA study group Abstract doi:10.1093/ecco-jcc/jjy222 Abstract P528 from the ‘Poster presentations’ section of the main abstract book has been withdrawn and…

Read More

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.

Related Articles Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Feb 19;: Authors: Drobne D, Kurent T, Golob S, Švegl P, Rajar P, Hanžel J, Koželj M, Novak G, Smrekar N, Ferkolj I, Štabuc B Abstract BACKGROUND: Combination treatment with azathioprine for 6-12 months is the preferred strategy for starting infliximab due to improved pharmacokinetics. However, optimised infliximab monotherapy with proactive dose escalations in case of low trough levels is a safer but under-studied…

Read More

Comparative safety and effectiveness of tumor necrosis factor ╬▒ antagonists and vedolizumab in elderly IBD patients: a multicentre study.

Related Articles Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019 Feb 17;: Authors: Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN Abstract BACKGROUND: The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population. AIM: To compare safety…

Read More

Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.

Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. J Crohns Colitis. 2019 Feb 14;: Authors: Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW Abstract INTRODUCTION: Vedolizumab is…

Read More
<< Go Back